Research shows Australians are increasingly positive about nanotechnology

22 August 2011

Australians are increasingly positive about nanotechnology, in particular its potential to improve people’s lives, according to a study by independent company Market Attitude Research Services.

Nanotechnology is the science of the very small, using materials at the scale of one ten-thousandth the width of a human hair. At this size the properties of materials can change, and they can be used to develop new products or processes - like nanoscale silver that is antimicrobial, or nano-sized medicines that can target individual cells.

Releasing the findings of a study of public attitudes towards nanotechnologies, Australia’s Innovation Minister Senator Kim Carr said the Gillard Labor government was working with researchers and industry to ensure the benefits of nanotechnology were realized, while ensuring any risks were identified and managed. This study is the fifth conducted since 2005 and in that time we have found the understanding of nanotechnology is increasing, he noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical